|1.||Whitehouse, Michael W: 1 article (01/2005)|
|2.||Wakamatsu, Shingo: 1 article (08/2002)|
|3.||Kumagai, Norio: 1 article (08/2002)|
|4.||Sakai, Yoko: 1 article (08/2002)|
|5.||Ono, Koji: 1 article (08/2002)|
02/01/1993 - "The aim was to test the efficacy of the immune system modulator lobenzarit disodium in the treatment of coxsackievirus B3 myocarditis. "
02/01/1993 - "Lobenzarit disodium decreased splenic pan T cells and aggravated both clinical course and cardiac pathology in acute murine coxsackievirus B3 myocarditis."
02/01/1993 - "Enhancement of coxsackievirus B3 myocarditis in mice by lobenzarit disodium through inhibition of splenic pan T cells."
01/01/1993 - "The effects of lobenzarit disodium, a novel immunomodulator, upon murine coxsackievirus B3 myocarditis."
08/01/1992 - "Effects of lobenzarit on murine acute viral myocarditis."
01/01/1995 - "Lobenzarit disodtulIl (CCA) is a novel immunomodulatory drug useful in the treatment of chronic inflammations. "
01/01/2005 - "Drugs to treat inflammation are discussed under the following headings: (1) random discoveries covering copper, salicylates, heterocyclic diones, ACTH, adrenal steroids and disease-modifying agents (DMARDs); these include Au(I)-thiolates, chloroquine, and hydroxychloroquine, minocycline, cyclosporin, salazopyrine, D-penicillamine and methotrexate; (2) programmed NSAID developments covering salicylates and fenamates, arylalkanoates, diones, non-acidic NSAIDs, clozic, lobenzarit and coxibs; (3) synthetic glucocorticosteroids; and (4) 'Biologicals' for neutralising pro-inflammatory cytokines. "
10/01/1984 - "A multicenter double-blind controlled study of lobenzarit, a novel immunomodulator, in rheumatoid arthritis."
02/01/1999 - "Lobenzarit disodium is a drug for the treatment of rheumatoid arthritis. "
03/01/1997 - "Lobenzarit disodium (LBZ) is an immunomodulator and antioxidative drug developed and used successfully in Japan for the treatment of rheumatoid arthritis (RA). "
02/01/1992 - "Lobenzarit (disodium 4-chloro-2,2'-iminodibenzoate [CCA]) is a novel disease-modifying drug for the treatment of rheumatoid arthritis (RA). "
10/01/1984 - "A multicenter double-blind study was carried out in patients with rheumatoid arthritis (RA) by comparing treatment with a novel immunomodulator, lobenzarit, disodium 4-chloro-2, 2'-iminodibenzoate, with an inert placebo. "
04/01/1996 - "Complete prevention of the clinical expression of adjuvant-induced arthritis in rats by cyclosporin-A and lobenzarit: the regulation of lymph node cell populations and cytokine production."
01/01/1981 - "Depressed natural killer activity in rheumatoid arthritis and its in vitro augmentation with interferon and N-(2-carboxyphenyl)-4-chloroanthranilic acid disodium salt (CCA), an anti-arthritis agent."
01/01/1986 - "Immunopharmacological study of CCA (Lobenzarit disodium), an anti-arthritis agent--I. Abrogation of IL 1 secretion by LPS-stimulated human monocytes and induction of gamma-interferon production with CCA."
07/01/1995 - "The effects of Ta-383 (0.016, 0.08, 0.4, 2 and 10 mg/kg) and anti-rheumatic drugs (lobenzarit 10 and 50 mg/kg, dexamethasone 0.25 mg/kg) were evaluated on type II collagen-induced arthritis in DBA/1J mice. "
01/01/1991 - "The effects of anti-rheumatic drugs (lobenzarit (CCA); 10 and 50mg/kg, cyclophosphamide (CP); 5 mg/kg and dexamethasone (DM); 0.25mg/kg) were evaluated immunologically and histopathologically on DBA/1J mice that develop polyarthritis after immunization by the intradermal injection of type II collagen. "
|2.||Interferon-gamma (Interferon, gamma)
|3.||Immunologic Factors (Immunomodulators)
|4.||3-chloro-4,4-dimethyl-2-oxazolidinone (agent I)
|7.||Collagen Type II (Type II Collagen)
|8.||Antirheumatic Agents (DMARD)